Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CUE-101 |
Synonyms | |
Therapy Description |
CUE-101 is a fusion protein consisting of an HLA-A*0201 complex linked to an HPV16 E7 epitope (aa 11-20), a reduced affinity version of interleukin-2, and an effector attenuated IgG1 Fc domain, which binds to HPV16 E7-specific T-cells, potentially activating a T-cell response against HPV16 E7-positive tumor cells (PMID: 31964784). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CUE-101 | CUE101|CUE 101|anti-HPV16 E7 fusion protein CUE-101 | CUE-101 is a fusion protein consisting of an HLA-A*0201 complex linked to an HPV16 E7 epitope (aa 11-20), a reduced affinity version of interleukin-2, and an effector attenuated IgG1 Fc domain, which binds to HPV16 E7-specific T-cells, potentially activating a T-cell response against HPV16 E7-positive tumor cells (PMID: 31964784). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04852328 | Phase II | CUE-101 | Three Schedules of CUE-101 Administered Before Surgery or Definitive Chemoradiation Therapy in HLA-A*0201 Positive Patients With Locally Advanced, HPV16-Positive Oropharyngeal Squamous-Cell Carcinoma | Recruiting | USA | 0 |
NCT03978689 | Phase I | CUE-101 + Pembrolizumab CUE-101 | A Phase 1 Study in Patients With HPV16+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma | Active, not recruiting | USA | 0 |